A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT06747338, led by Shanghai JMT-Bio, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer. Planned enrolment is 520 participants (estimated). The study started in 2024-12-16 and primary completion is expected in 2026-12-16. No results have been posted on ClinicalTrials.gov.